JP2010519915A - 二本鎖のロックされた核酸組成物 - Google Patents

二本鎖のロックされた核酸組成物 Download PDF

Info

Publication number
JP2010519915A
JP2010519915A JP2009552038A JP2009552038A JP2010519915A JP 2010519915 A JP2010519915 A JP 2010519915A JP 2009552038 A JP2009552038 A JP 2009552038A JP 2009552038 A JP2009552038 A JP 2009552038A JP 2010519915 A JP2010519915 A JP 2010519915A
Authority
JP
Japan
Prior art keywords
lna
formula
nucleoside
integer
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2009552038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519915A5 (enExample
Inventor
ピーター エムテイジ
Original Assignee
ヌヴェンタ バイオファーマシューティカルズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヌヴェンタ バイオファーマシューティカルズ コーポレイション filed Critical ヌヴェンタ バイオファーマシューティカルズ コーポレイション
Publication of JP2010519915A publication Critical patent/JP2010519915A/ja
Publication of JP2010519915A5 publication Critical patent/JP2010519915A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2009552038A 2007-03-07 2008-03-07 二本鎖のロックされた核酸組成物 Abandoned JP2010519915A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90546107P 2007-03-07 2007-03-07
US95027107P 2007-07-17 2007-07-17
PCT/CA2008/000473 WO2008106803A1 (en) 2007-03-07 2008-03-07 Double-stranded locked nucleic acid compositions

Publications (2)

Publication Number Publication Date
JP2010519915A true JP2010519915A (ja) 2010-06-10
JP2010519915A5 JP2010519915A5 (enExample) 2011-10-27

Family

ID=39737757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009552038A Abandoned JP2010519915A (ja) 2007-03-07 2008-03-07 二本鎖のロックされた核酸組成物

Country Status (10)

Country Link
US (1) US20090041809A1 (enExample)
EP (1) EP2125853A1 (enExample)
JP (1) JP2010519915A (enExample)
KR (1) KR20100051041A (enExample)
CN (1) CN101687900A (enExample)
AU (1) AU2008222523A1 (enExample)
BR (1) BRPI0808442A2 (enExample)
CA (1) CA2680060A1 (enExample)
MX (1) MX2009009530A (enExample)
WO (1) WO2008106803A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532976A (ja) * 2010-06-25 2013-08-22 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｏｌｌ様レセプター３の新規アゴニストおよびその使用方法

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228540D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compositions
WO2009149465A1 (en) 2008-06-06 2009-12-10 Aurora Biofuels, Inc. Transformation of algal cells
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
CN105477650A (zh) 2009-03-19 2016-04-13 Emd密理博公司 使用纳米纤维过滤介质从流体样品除去微生物
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US8865468B2 (en) 2009-10-19 2014-10-21 Aurora Algae, Inc. Homologous recombination in an algal nuclear genome
US8809046B2 (en) 2011-04-28 2014-08-19 Aurora Algae, Inc. Algal elongases
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
US8709765B2 (en) 2009-07-20 2014-04-29 Aurora Algae, Inc. Manipulation of an alternative respiratory pathway in photo-autotrophs
CA2776386C (en) * 2009-10-02 2018-02-27 The Trustees Of Columbia University In The City Of New York Piscine reovirus immunogenic compositions
US8846388B2 (en) * 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
US9623352B2 (en) 2010-08-10 2017-04-18 Emd Millipore Corporation Method for retrovirus removal
PL2655612T3 (pl) 2010-12-23 2017-12-29 Shell Internationale Research Maatschappij B.V. Czynniki uszkadzające geny produkujące pochodne tłuszczowego acylo-coa
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
US8722359B2 (en) 2011-01-21 2014-05-13 Aurora Algae, Inc. Genes for enhanced lipid metabolism for accumulation of lipids
SG10201605328WA (en) 2011-04-01 2016-08-30 Emd Millipore Corp Nanofiber containing composite structures
JP2014519810A (ja) 2011-04-28 2014-08-21 オーロラ アルギー，インコーポレイテッド 藻類のデサチュラーゼ
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013166065A1 (en) 2012-04-30 2013-11-07 Aurora Algae, Inc. ACP Promoter
US9157101B2 (en) * 2012-12-21 2015-10-13 Algenol Biotech LLC Cyanobacterium sp. for production of compounds
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
EP3835419A1 (en) 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
SG11201608399QA (en) 2014-06-26 2016-11-29 Emd Millipore Corp Filter structure with enhanced dirt holding capacity
WO2016061131A1 (en) 2014-10-14 2016-04-21 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
MX2017008289A (es) 2014-12-23 2017-10-02 Algenol Biotech LLC Metodos para aumentar la estabilidad de la produccion de compuestos en celulas huesped microbianas.
KR20170113638A (ko) 2015-04-17 2017-10-12 이엠디 밀리포어 코포레이션 접선방향 유동 여과 모드에서 작동되는 나노섬유 한외여과막을 사용하여 샘플에서 목적하는 생물학적 물질을 정제하는 방법
EP3303634B1 (en) 2015-06-03 2023-08-30 The Regents of The University of California Cas9 variants and methods of use thereof
US10138489B2 (en) 2016-10-20 2018-11-27 Algenol Biotech LLC Cyanobacterial strains capable of utilizing phosphite
WO2019016605A1 (en) 2017-07-21 2019-01-24 Merck Millipore Ltd MEMBRANES OF NONWOVEN FIBERS
EP3690030A4 (en) 2017-09-28 2021-06-23 Industry-Academic Cooperation Foundation, Yonsei University METHOD FOR MANUFACTURING MYELOID-DERIVED SUPPRESSOR CELLS, SUPPRESSOR CELLS MANUFACTURED FROM MYEOLID AND USES THEREOF
EP3788147A1 (en) * 2018-05-04 2021-03-10 Tollys Tlr3 ligands that activate both epithelial and myeloid cells
EP3841205A4 (en) 2018-08-22 2022-08-17 The Regents of The University of California Variant type v crispr/cas effector polypeptides and methods of use thereof
EP3877517A4 (en) 2018-11-09 2022-09-07 Inari Agriculture, Inc. RNA-DRIVEN NUCLEASES AND DNA-BINDING PROTEINS
EP4219700A1 (en) 2019-03-07 2023-08-02 The Regents of the University of California Crispr-cas effector polypeptides and methods of use thereof
KR102256001B1 (ko) * 2019-07-02 2021-05-26 주식회사 엔에이백신연구소 신규한 리보핵산 및 이를 기반으로 하는 약제학적 조성물
WO2021002688A1 (en) * 2019-07-02 2021-01-07 Na Vaccine Institute Novel ribonucleic acid and pharmaceutical composition based on the same
WO2022036255A1 (en) * 2020-08-14 2022-02-17 Allen Institute Artificial expression constructs for modulating gene expression in striatal neurons
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692899A (en) * 1969-12-17 1972-09-19 Us Health Education & Welfare Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice
US4024241A (en) * 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US3952097A (en) * 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4349538A (en) * 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
JP3756313B2 (ja) * 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CA2203843C (en) * 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6083482A (en) * 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
AU2003203079B8 (en) * 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
WO2005102278A1 (en) * 2002-07-03 2005-11-03 Oncovir, Inc. Method for preparation of poly-iclc and uses thereof
GB0228540D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compositions
CA2542232A1 (en) * 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Method for treating neurodegenerative disease by inhibiting alpha-synuclein
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
JP5409005B2 (ja) * 2005-10-27 2014-02-05 ロゼッタ インファーマティックス エルエルシー 非ランダムプライマーを用いる核酸増幅
EP1951737A4 (en) * 2005-11-01 2009-07-01 Alnylam Pharmaceuticals Inc INHIBITION OF INFLUENZA VIRUS REPLICATION BY RNA INTERFERENCE

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532976A (ja) * 2010-06-25 2013-08-22 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｏｌｌ様レセプター３の新規アゴニストおよびその使用方法

Also Published As

Publication number Publication date
AU2008222523A1 (en) 2008-09-12
MX2009009530A (es) 2010-05-19
BRPI0808442A2 (pt) 2014-08-05
CN101687900A (zh) 2010-03-31
CA2680060A1 (en) 2008-09-12
US20090041809A1 (en) 2009-02-12
WO2008106803A1 (en) 2008-09-12
EP2125853A1 (en) 2009-12-02
KR20100051041A (ko) 2010-05-14

Similar Documents

Publication Publication Date Title
US20090041809A1 (en) Double-stranded locked nucleic acid compositions
ES2526879T3 (es) Composiciones y procedimientos para formulaciones de oligonucleótidos
ES2380796T3 (es) Oligonucleótidos inmunoestimuladores y sus usos.
CA2570786C (en) Modified cpg-containing oligonucleotide multimers in immune stimulation
US20110038888A1 (en) Adjuvant compositions comprising poly-ic and a cationic polymer
KR101092043B1 (ko) 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
US7566702B2 (en) Immunostimulatory oligonucleotide multimers
WO2015013675A9 (en) Spherical nucleic acid-based constructs as immunoregulatory agents
CN101287742A (zh) 基于变异应答调制Toll样受体的免疫调节寡核苷酸（IRO）化合物
US10066230B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
CN112203663A (zh) Cpg两亲分子及其用途
JP2009538836A (ja) 生物活性の精製ＨｓｐＥ７組成物
EP1657307A1 (en) Oligonucleotides that induce the secretion of GM-CSF
JP5415724B2 (ja) 一種のオリゴヌクレオチド及びその応用
JPWO2009069682A1 (ja) 肝炎の治療剤又は予防剤
WO2022094102A1 (en) Immunostimulatory oligonucleotides for the prevention and treatment of covid-19
CN101378776A (zh) 含有CG二核苷酸修饰的TOll样受体的新合成拮抗剂
CN117568339A (zh) CpG寡核苷酸及其应用
JP2014073126A (ja) 一種のオリゴヌクレオチド及びその応用
CA2487904A1 (en) Immunostimulatory oligonucleotides and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110909

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20120105